Olema Pharmaceuticals, Inc.

Olema Oncology, operating as Olema Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of targeted therapies for women's cancers, particularly breast cancer and other endocrine-driven cancers. The company's mission is to transform the standard of care and improve outcomes for patients living with breast cancer and beyond. Headquartered in San Francisco, California, Olema Oncology also maintains operations in Cambridge, Massachusetts.

Olema Oncology's pipeline features two primary product candidates: palazestrant (OP-1250) and OP-3136. Palazestrant is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD), designed to block estrogen receptor activity regardless of ESR1 mutation status. It is currently being evaluated in pivotal Phase 3 clinical trials, OPERA-01 and OPERA-02, for ER+/HER2- metastatic breast cancer, and has received FDA Fast Track designation. OP-3136 is an earlier-stage, potent, selective oral inhibitor of lysine acetyltransferase 6 (KAT6), which is being investigated in Phase 1 clinical trials for breast and other solid tumors.

In recent news, Olema Oncology appointed Prakash Raman, Ph.D., to its Board of Directors in April 2026, bringing extensive biopharmaceutical leadership experience to the company. The company is also slated to present initial clinical data for OP-3136 at the 2026 ASCO Annual Meeting and preclinical data for both palazestrant and OP-3136 at the 2026 AACR Annual Meeting. Olema Oncology has strengthened its financial position through a $250 million funding round and a collaboration with Novartis for the Phase 3 OPERA-02 trial, which will evaluate palazestrant in combination with ribociclib. Sean P. Bohen, M.D., Ph.D., serves as the President and CEO, guiding the company's efforts to advance its clinical programs and enhance its market positioning in oncology.